{"id":24952,"date":"2026-06-23T19:00:00","date_gmt":"2026-06-23T17:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=e290fe0deaa3ea0a273d7966938660d1"},"modified":"2026-06-23T19:00:00","modified_gmt":"2026-06-23T17:00:00","slug":"highres-and-waters-collaborate-to-advance-drug-discovery-through-robotic-automation","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=24952","title":{"rendered":"HighRes\u00ae and Waters Collaborate to Advance Drug Discovery through Robotic Automation"},"content":{"rendered":"

\n\u00a0<\/p><\/a><\/a>

BEVERLY, Mass.--(BUSINESS WIRE)--HighRes\u00ae<\/sup> today announced a strategic collaboration to enable robotic capabilities on Waters Biosciences, formerly BD Biosciences, flow cytometers to automate key experimental steps and streamline research workflows, from basic research to drug discovery.<\/p>

\nThe companies are integrating the BD FACSLyric\u2122 Flow Cytometer1<\/sup> with the HighRes Nucleus\u00ae<\/sup> Automation and Cellario\u00ae<\/sup> Software Platforms, enabling scientists to utilize robotic arm capabilities to run reliable, complex, multi-step experiments unattended with continuous operation of up to three times more experimental runs per day. The integration enables higher-throughput studies, improves reproducibility, and allows for greater operational efficiency.<\/p>

\n\"The BD FACSLyric\u2122 Flow Cytometer, when paired with HighRes automation, is an ideal solution for laboratories running complex flow cytometry studies that demand scale and precision, including for higher volumes of experiments,\" said Eric Diebold, Vice President and General Manager, Instruments & informatics, Waters Biosciences, Waters Corporation. \"This collaboration exemplifies our long-term commitment to advancing robotic automation across our complete portfolio of flow cytometers, unlocking a new dimension of automation for research and biopharma partners aiming to bring their potentially life-changing therapies to market even faster.\u201d<\/p>

\n\u201cWith this collaboration, scientists can run more experiments per day with consistent quality, reduce hands-on time from hours to minutes, and design assays that were previously too complex or time-sensitive to automate \u2013 with every step tracked for complete data integrity and reproducibility,\u201d said Ira Hoffman, CEO, HighRes. \u201cBy combining BD\u2019s expertise in flow cytometry and HighRes\u2019 leadership in lab automation, we are enabling more labs around the world to operate with true end-to-end confidence.\u201d<\/p>

\nLabs interested in deploying the BD FACSLyric\u2122 with HighRes automation can schedule a consultation today. More information can be found at highres.com<\/a>.<\/p>

\nAbout HighRes<\/b><\/p>

\nHighRes partners with life science organizations to implement intelligent data and lab automation workflows that empower every team member to plan and execute efficient and reproducible science. Visit our website to learn more at highres.com<\/a>.<\/p>

\n1<\/sup> RUO disclaimer for US: BD FACSLyric\u2122 Flow Cytometers are Class 1 Laser Products. The BD FACSLyric\u2122 Flow Cytometer is For Research Use Only. Not for use in diagnostic or therapeutic procedures.<\/p> Contacts<\/b>

\nThomas Rawlins\nTRawlins@HighRes.com<\/a>+1 (508) 212-4881\nVP, Marketing\nHighRes<\/p>","protected":false},"excerpt":{"rendered":"

\u00a0BEVERLY, Mass.–(BUSINESS WIRE)–HighRes\u00ae today announced a strategic collaboration to enable robotic capabilities on Waters Biosciences, formerly BD Biosciences, flow cytometers to automate key experimental steps and streamline research workflows, f…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24952","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24952"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24952\/revisions"}],"predecessor-version":[{"id":24953,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24952\/revisions\/24953"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}